What we're reading, February 19, 2016: long-term hospice care is weighing on Medicare; both the pope and the World Health Organization suggest women in Zika infected countries have access to contraception; and Texas health official steps down after co-authoring study on Planned Parenthood.
Although the Medicare hospice program is supposed to cover patients with 6 months or less to live, care is being routinely extended to patients with ailments whose declines cane take years. The Wall Street Journal reported that between 2005 and 2013, more than 100,000 patients received hospice care for nearly 1000 days over the course of 4 or more years. Although these patients account for just 1.3% of Medicare’s hospice patients, they cost the program 14% of its overall hospice spending.
With cases of the Zika virus multiplying in Latin America, 2 very different authorities have suggested the use of contraception. The World Health Organization issued a call for women in countries with the Zika virus to have access to emergency contraception, and Pope Francis suggested that the use of contraceptives may be morally acceptable to prevent the spread of the virus. The pope, returning from Mexico, made it clear that abortion was absolutely out of the question, but that contraception to prevent pregnancies may be a solution.
After co-authoring a study that suggested cuts to Planned Parenthood restricted access to women’s healthcare in Texas, a state health official is stepping down from his post. According to The New York Times, the official broke policy by working on the study during taxpayer time and he faced strong criticism from Republicans. The official is eligible for retirement and will leave in March.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More